Drug intelligence / Profile preview

LPALS-04

Development stage: Preclinical
Lead developer: Lysat Pharma
Modality: Cell Therapies

Overview

LPALS-04 is a preclinical-stage biologic candidate developed by Lysatpharma for the treatment of Amyotrophic Lateral Sclerosis (ALS). The therapeutic is a lysate-based cell preparation, utilizing a patented process to extract bioactive components from cells. This approach aims to harness a complex mixture of proteins, lipids, and other signaling molecules to exert neuroprotective effects and potentially modulate the neuroinflammatory environment characteristic of ALS. As of early 2024, the specific molecular targets and the exact cell source of the lysate have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on LPALS-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPALS-04.

Explore the full profile